Jazz Pharmaceuticals to initiate study of JZP-458 to treat ALL
Jazz Pharmaceuticals is set to initiate a single-arm, pivotal Phase II/III study of JZP-458 as a potential treatment option for…

Jazz Pharmaceuticals is set to initiate a single-arm, pivotal Phase II/III study of JZP-458 as a potential treatment option for…
PeptiDream has entered an agreement with Shionogi for identifying and developing a series of blood-brain barrier (BBB) penetrating peptide drug…
MabSpace Biosciences has merged with HJB to create a fully-integrated biotherapeutics company named Transcenta Holding.
Thank you for subscribing to Clinical Trials Arena